Ultime notizie per Trupanion (NASDAQ:TRUP) Azioni

Trupanion

Trupanion Inc is a specialty insurance products provider in the United States. Its core business is the sale of insurance products tailor-made for pets, especially cats and dogs. It operates in two business segments: The subscription business segment generates revenue primarily from subscription fees related to the Company's direct-to-consumer products and Other business segment is comprised of revenue from other product offerings that generally have a business-to-business relationship and a different margin profile than subscription business segment, including revenue from writing policies on behalf of third parties and revenue from other products and software solutions.

Piper Sandler analyst John Barnidge maintains Trupanion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUP#NASDAQ">TRUP</a>) with a Overweight and raises the price target from $52 to $62.

News

Price Target

Analyst Ratings

TRUP

Piper Sandler Maintains Overweight on Trupanion, Raises Price Target to $62

Lake Street analyst Mark Argento maintains Trupanion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUP#NASDAQ">TRUP</a>) with a Buy and lowers the price target from $65 to $60.

Lake Street Maintains Buy on Trupanion, Lowers Price Target to $60

U.S. stocks were higher, with the Dow Jones index gaining around 400 points on Friday.
Shares of Trupanion, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUP#NASDAQ">TRUP</a>) rose sharply during Friday's session after the company reported better-than-expected first-quarter financial results and <a href="https://www.benzinga.com/quote/TRUP/earnings">raised its FY25 sales guidance</a>.
Trupanion reported quarterly loss of 3 cents per share which beat the analyst consensus estimate of loss of 5 cents per share. The company reported quarterly sales of $341.98 million which beat the analyst consensus estimate of $337.82 million.
Trupanion shares jumped 18.2% to $43.08 on Friday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul>
<li>Adaptive Biotechnologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) shares surged 30% to $9.60 after the company reported first-quarter financial results and beat its EPS and revenue estimates.</li>
<li>NPK International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NPKI#NASDAQ">NPKI</a>) gained 26.6% to $7.65 after the company reported better-than-expected first-quarter financial results.</li>
<li>Wolfspeed, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) rose 23.1% to $4.42.</li>
<li>Highest Performances Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HPH#NASDAQ">HPH</a>) gained 23.1% to $7.20.</li>
<li>Pony AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>) rose 20.8% to $10.37.</li>
<li>AST SpaceMobile, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) climbed 17.4% to $26.96.</li>
<li>iRhythm Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRTC#NASDAQ">IRTC</a>) rose 17.4% to $127.43 after the company reported better-than-expected first-quarter results and raised its FY25 sales guidance</li>
<li>Duolingo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOL#NASDAQ">DUOL</a>) gained 15% to $460.50 after the company reported better-than-expected first-quarter financial results and raised its FY25 sales guidance.</li>
<li>DexCom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) gained 13.7% to $79.87 following strong quarterly sales.</li>
<li>Aurora Innovation, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUR#NASDAQ">AUR</a>) jumped 12.4% to $7.74.</li>
<li>Maplebear Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CART#NASDAQ">CART</a>) gained 11.3% to $44.33 following first-quarter results.</li>
<li>Exact Sciences Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) gained 11.1% to $52.40 after the company reported better-than-expected first-quarter sales results and raised its FY25 sales guidance.</li>
<li>Archer Aviation Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>) gained 10.6% to $9.39.</li>
<li>MasTec, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTZ#NYSE">MTZ</a>) gained 6.4% to $142.68 following first-quarter results.</li>
<li>Robinhood Markets, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) rose 6.3% to $49.58.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/05/45164963/how-to-earn-500-a-month-from-tyson-foods-stock-ahead-of-q2-earnings">How To Earn $500 A Month From Tyson Foods Stock Ahead Of Q2 Earnings</a></li>
</ul>

Intraday Update

Markets

Movers

Trading Ideas

ACHR

ADPT

ASTS

CART

DUOL

DXCM

EXAS

HOOD

IRTC

NPKI

PONY

WOLF

Trupanion Posts Better-Than-Expected Results, Joins Duolingo, DexCom, Exact Sciences And Other Big Stocks Moving Higher On Friday

WIIM

Trupanion shares are trading higher after the company reported better-than-expected Q1 financial results, issued Q2 sales guidance above estimates, and raised its FY25 sales guidance.

Trupanion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUP#NASDAQ">TRUP</a>) raises FY2025 sales outlook from $1.38 billion-$1.41 billion to $1.39 billion-$1.43 billion vs $1.39 billion estimate.

Guidance

Trupanion Raises FY2025 Sales Guidance from $1.38B-$1.41B to $1.39B-$1.43B vs $1.39B Est

Trupanion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUP#NASDAQ">TRUP</a>) sees Q2 sales of $344.000 million-$350.000 million vs $341.80 million analyst estimate.

Trupanion Sees Q2 Sales $344.000M-$350.000M vs $341.80M Est

Trupanion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUP#NASDAQ">TRUP</a>) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.05) by 40 percent. This is a 81.25 percent increase over losses of $(0.16) per share from the same period last year. The company reported quarterly sales of $341.98 million which beat the analyst consensus estimate of $337.82 million by 1.23 percent. This is a 11.71 percent increase over sales of $306.12 million the same period last year.

Earnings

Earnings Beats

Trupanion Q1 EPS $(0.03) Beats $(0.05) Estimate, Sales $341.98M Beat $337.82M Estimate

AAMI

AAPL

ABNB

ACCO

AGCO

AGIO

ALHC

ALKS

ALNY

ALSN

AMGN

AMWL

AMZN

APLE

APTV

ARDX

ARVN

ASND

ASPS

ASUR

ATEC

ATEN

AXTI

BBAI

BIIB

BJRI

BLDR

BMRN

BOOM

BPMC

BRFH

CABO

CARR

CERS

CMLS

COHN

COHU

COLM

COMM

COOK

CRAI

CTRE

CUBE

CWST

DBRG

DINO

DSGR

ECVT

ELME

Earnings Scheduled For May 1, 2025

Brighthouse Financial, Inc. - Common Stock

BWIN

CINF

ERIE

GSHD

HUIZ

ITIC

KMPR

KNSL

LMND

OSCR

PLMR

ROOT

RYAN

SKWD

TWFG

ZBAO

Shares of insurance companies are trading higher following President Trump's decision to implement a 90-day pause on reciprocal tariffs for all countries except China.

SAN AIG BOH ING
&nbsp;
&nbsp;

ALLY

CUBI

GOCO

HBAN

HSBC

LPLA

MNSB

MUFG

SBNY

SCHW

SMFG

SOFI

TROW

Shares of several banking and broader financial stocks are trading higher in sympathy with overall market sentiment after the Fed policy decision to keep rates unchanged.

Trupanion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUP#NASDAQ">TRUP</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Trupanion, revealing an average target of $48.5, a high estimate of $57.00, and a low estimate of $41.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 3.0%. 
<img src="https://www.benzinga.com/files/images/story/2025/1740078093_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Trupanion. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jonathan Block</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$41.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>John Barnidge</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$52.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>John Barnidge</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$57.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Jonathan Block</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$44.00</td>
<td>$42.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Trupanion. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Trupanion compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Trupanion's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Trupanion's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/TRUP/analyst-ratings?utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Trupanion analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Trupanion</h2>
Trupanion Inc is a specialty insurance products provider in the United States. Its core business is the sale of insurance products tailor-made for pets, especially cats and dogs. It operates in two business segments: The subscription business segment generates revenue primarily from subscription fees related to the Company's direct-to-consumer products and Other business segment is comprised of revenue from other product offerings that generally have a business-to-business relationship and a different margin profile than subscription business segment, including revenue from writing policies on behalf of third parties and revenue from other products and software solutions.
<h3>Trupanion: A Financial Overview</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Trupanion's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 14.55% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 0.44%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Trupanion's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 0.46%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Trupanion's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.18%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Trupanion's debt-to-equity ratio stands notably higher than the industry average, reaching 0.4. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing Trupanion: Insights From 4 Financial Analysts

Stifel analyst Jonathan Block maintains Trupanion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUP#NASDAQ">TRUP</a>) with a Hold and lowers the price target from $44 to $41.

Stifel Maintains Hold on Trupanion, Lowers Price Target to $41

Trupanion shares are trading lower after the company reported worse-than-expected Q4 EPS results and Piper Sandler cut its price target on the stock from $57 to $52.

Piper Sandler analyst John Barnidge maintains Trupanion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUP#NASDAQ">TRUP</a>) with a Overweight and lowers the price target from $57 to $52.

Piper Sandler Maintains Overweight on Trupanion, Lowers Price Target to $52

Trupanion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUP#NASDAQ">TRUP</a>) reported quarterly earnings of $0.04 per share which missed the analyst consensus estimate of $0.07 by 42.86 percent. This is a 180 percent increase over losses of $(0.05) per share from the same period last year. The company reported quarterly sales of $337.31 million which beat the analyst consensus estimate of $335.41 million by 0.57 percent. This is a 14.01 percent increase over sales of $295.86 million the same period last year.

Earnings Misses

Trupanion Q4 EPS $0.04 Misses $0.07 Estimate, Sales $337.31M Beat $335.41M Estimate

ACVA

AMPL

ANSS

APPN

BLCO

BORR

CAKE

CCAP

CCSI

CHDN

CLVT

CMTG

CVNA

CWAN

ENLT

ENVX

ESRT

ETSY

FOLD

First Trust Advantage Preferred Income Fund

FVRR

GLBE

GRAB

GRMN

ICLR

IIPR

IMAX

INSG

IONS

KALU

KPTI

KRYS

KVYO

LAND

LILA

LILAK

LOPE

LUNG

MANU

MATV

MGRC

MTRN

NDSN

NRDS

NYMT

OBDC

PAAS

PERI

PNST

PRAA

Earnings Scheduled For February 19, 2025

While investor sentiment <a href="https://www.benzinga.com/topic/pet-insurance">for pet insurance provider</a> Trupanion Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUP#NASDAQ">TRUP</a>) is improving due to a decline in the company's input costs, the stock has several "catalysts on the horizon," according to Piper Sandler.
The Trupanion Analyst: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5a047addefacff0001df2095/john-barnidge">Analyst John Barnidge</a> upgraded the rating for Trupanion from Neutral to Overweight, while maintaining the price target at $57.
The Trupanion Thesis: Investors now have a better understanding of the drag from Pet's Best on the company's 2025, Barnidge said in the upgrade note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
On the other hand, Trupanion's underlying Subscription business "retains strong growth characteristics," he added.
Continued compounding of multi-year interest rate hikes have led to a faster improvement in underwriting, while higher speed of claims processing may support the "meeting of the growth demands for a growing product category," the analyst stated.
A year back, investors were concerned about "two material weaknesses &#8211; one in financial controls and the other on tech," which may be lifted by Trupanion's 2024 10-K filing showing that the company has taken remediation actions, Barnidge wrote.
The stock is currently trading at lower multiples than "many insurance brokers," he added.
TRUP Price Action: Shares of Trupanion had risen by3.72% to $48.25 at the time of publication on Thursday.
Read More: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/43068088/allstate-chubb-progressive-face-significant-losses-from-wildfires-weather-events-say-analysts-ahead-of-q4-reports">Allstate, Chubb, Progressive Face Significant Losses From Wildfires, Weather Events Say Analysts Ahead Of Q4 Reports</a></li>
</ul>
Image: Shutterstock

Analyst Color

Long Ideas

Upgrades

Insurance

Pet Insurer Trupanion Has Several Catalysts For 2025 As Investor Sentiment Improves: Analyst

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Jefferies analyst Brian Tanquilut upgraded the rating for Option Care Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPCH#NASDAQ">OPCH</a>) from Hold to Buy and raised the price target from $26 to $35. Option Care Health shares closed at $29.31 on Wednesday. <a href="https://www.benzinga.com/quote/OPCH/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley analyst Erik Woodring upgraded Logitech International S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOGI#NASDAQ">LOGI</a>) from Underweight to Equal-Weight and raised the price target from $73 to $92. Logitech shares closed at $87.85 on Wednesday. <a href="https://www.benzinga.com/quote/LOGI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler analyst Alexander Potter upgraded the rating for Aptiv PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APTV#NYSE">APTV</a>) from Underweight to Neutral and boosted the price target from $53 to $65 Aptiv shares closed at $62.73 on Wednesday. <a href="https://www.benzinga.com/quote/APTV/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Raymond James analyst Steve Moss upgraded First Community Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCCO#NASDAQ">FCCO</a>) from Outperform to Strong Buy and raised the price target from $27 to $30. First Community shares closed at $24.57 on Wednesday. <a href="https://www.benzinga.com/quote/FCCO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler analyst John Barnidge upgraded the rating for Trupanion, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUP#NASDAQ">TRUP</a>) from Neutral to Overweight and maintained the price target of $57. Trupanion shares closed at $46.52 on Wednesday. <a href="https://www.benzinga.com/quote/TRUP/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying LOGI stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="612" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23072322/image-168-1024x612.png" alt="" class="wp-image-746628" style="width:552px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23072322/image-168-1024x612.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23072322/image-168-300x179.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23072322/image-168-768x459.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23072322/image-168.png 1107w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43126364/jim-cramer-this-tech-stock-is-a-buy-amd-is-a-great-company">Jim Cramer: AMD Is A &#8216;Great&#8217; Company, Hold Onto Dow Inc.</a></li>
</ul>

Pre-Market Outlook

FCCO

LOGI

OPCH

This Logitech International Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Thursday

During the last three months, 4 analysts shared their evaluations of Trupanion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUP#NASDAQ">TRUP</a>), revealing diverse outlooks from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $52.0, along with a high estimate of $57.00 and a low estimate of $44.00. This current average reflects an increase of 10.05% from the previous average price target of $47.25. 
<img src="https://www.benzinga.com/files/images/story/2025/1737633636_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Trupanion among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Barnidge</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$57.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Jonathan Block</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$44.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Greg Gibas</td>
<td>Northland Capital Markets</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$50.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>John Barnidge</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$57.00</td>
<td>$45.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Trupanion. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Trupanion compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Trupanion's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Trupanion's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/TRUP/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Trupanion analyst ratings.</a>
<h2>Unveiling the Story Behind Trupanion</h2>
Trupanion Inc is a specialty insurance products provider in the United States. Its core business is the sale of insurance products tailor-made for pets, especially cats and dogs. It operates in two business segments: The subscription business segment generates revenue primarily from subscription fees related to the Company's direct-to-consumer products and Other business segment is comprised of revenue from other product offerings that generally have a business-to-business relationship and a different margin profile than subscription business segment, including revenue from writing policies on behalf of third parties and revenue from other products and software solutions.
<h3>Financial Milestones: Trupanion's Journey</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Positive Revenue Trend: Examining Trupanion's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 14.55% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Trupanion's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 0.44%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Trupanion's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 0.46%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Trupanion's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.18%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Trupanion's debt-to-equity ratio surpasses industry norms, standing at 0.4. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Piper Sandler analyst John Barnidge upgrades Trupanion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUP#NASDAQ">TRUP</a>) from Neutral to Overweight and maintains the price target from $57 to $57.

Piper Sandler Upgrades Trupanion to Overweight, Maintains Price Target to $57

Press Releases

Trupanion Reports Fourth Quarter & Full Year 2024 Results

Comments

Trupanion

Notizie

Ultime notizie per Trupanion (NASDAQ:TRUP) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO